Get started
Jaguar Health, Inc.Jaguar Health, Inc.Jaguar Health, Inc.

Jaguar Health, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

JAGX trade ideas

$JAGX Jaquar Health RalliesAnalysts price target $5 | Overweight Short interest 8.2% Company Profile Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
NASDAQ:JAGX
by DEXWireNews
$JAGX BREAKOUT STOCK ON NEWS RELEASE****Jaguar Health Subsidiary Receiving Preclinical Services Funded by the National Institute of Allergy and Infectious Diseases in Support of Development of Lechlemer Drug Product Candidate for Cholera Indication******* COMPANY PROFILE Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
NASDAQ:JAGX
by RedHotStocks
1
$JAGX RALLY ON REFINANCING OF DEBT AGREEMENT ********HOT STOCK FOR THE DAYS TO COME ON THE BACK OF NEW DEBT REFINANCING AGREEMENT ANNOUNCED MONDAY. RALLY STALLED WITH THE MARKET BUT SHOULD SEE GREATER GAINS IN THE DAYS TO COME. BREAK ABOVE THE 50MA AND MACD CROSS NICE SIGNALS FOR A LONG. COMPANY PROFILE Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.
NASDAQ:JAGX
by DEXWireNews